



# REPORT ON THE RESULTS OF THE FOUNDATION'S ACTIVITIES


## 2019



[rakfond.org](http://rakfond.org)

**CANCER**  
foundation

Advancing the Day when  
Cancer is Defeated



# CONTENTS

1. Executive Summary
2. Operations Report
3. Fundraising and Financials
4. Partnerships and Collaborations
5. Contact Details

# **1. EXECUTIVE SUMMARY**

# DASHBOARD

## GRANTS & AWARDS

Competition of Research Projects in Oncoimmunology (slides 9-10):

Winners: 1                      Grant: 100 000 RUR

Competition of Clinical Research Projects (slides 11-12):

Winners : 2                      Grants: 713 000 RUR

Award for the Best Research (slide 13):

Amount: 1                      Award: 50 000 RUR

## FINANCIALS

Funds raised:	1 661 670.03 RUR
Expenditures:	1 458 124.91 RUR
• Grants:	863 000 RUR (59%)
• Administrative:	585 124.91 RUR (40%)
• Fundraising:	10 000 RUR (1%)

Details in slides 16-17

## TEAM

RakFond's team at rakfond.org

Boards:	- Directors:	3
	- Trustees:	5
	- Scientific Advisors:	18

Foundation's Director: Yuliya Atamanyuk

Volunteers: a team of permanent and temporary via ProCharity

## FUNDRAISING

Sources:	
• Non-profit ( <u>Nuzhna pomosch</u> )	735 596 RUR
• Corporate	401 748 RUR
• Individuals	290 326.03 RUR
• Meet For Charity auctions	234 000 RUR

## **2. OPERATIONS REPORT**

# YOUNG ONCOLOGIST COMPETITION: RESULTS

Jointly with the Russian Society of Clinical Oncology (RUSSCO)

## ALEXEY RUMYANTSEV



Federal Budgetary State Institution “N.N. Blokhin National Medical Research Center of Oncology”

**Project:** Phase II randomized trial to evaluate efficacy of olanzapine with short-acting 5HT3 inhibitors in chemotherapy-induced nausea & vomiting (CINV) prophylaxis

**Funding amount:** 232 500 rubles

**Description:** [http://www.rakfond.org/grants/rumyantsev-2018-01-ys-eci\\_en/](http://www.rakfond.org/grants/rumyantsev-2018-01-ys-eci_en/)

**Results:** <https://bit.ly/3cgcvSt>

## MARIYA STEPANOVA



State Clinical Hospital “St. Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological)”

**Project:** Development of diagnostic platform for monitoring of EGFR mutation C797S by RT-PCR cfDNA in patients with NSCLC

**Funding amount:** 250 000 rubles

**Description:** [http://www.rakfond.org/grants/stepanova-2018-01-ys-eci\\_en/](http://www.rakfond.org/grants/stepanova-2018-01-ys-eci_en/)

**Results:** <https://bit.ly/3ab79Gg>

# RESULTS OF THE SUPPORTED RESEARCH (1)

## A NEW EFFECTIVE AND AFFORDABLE WAY TO PREVENT CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING PROPOSED

JUNE 3, 2019 – CHICAGO, USA



The final results of the clinical trial were presented by its author **Alexey Rumyantsev** at the American Society of Clinical Oncology (ASCO) Annual Meeting at the Symptoms and Survivorship session. The session was chaired by distinguished experts from leading cancer centers (Dana-Farber Cancer Institute and Duke University).

ASCO Annual Meeting is the largest scientific event in oncology, which gathers tens of thousands of oncologists from all over the world. Dr. Rumyantsev's research has been selected for an **oral presentation** by the Scientific Program Committee from thousands of submitted abstracts.

Dr. Rumyantsev's presentation: <https://www.rakfond.org/en/2019/07/03/supported-research-at-asco2019/>



**Ученые из России выяснили, как можно подавить тошноту при химиотерапии**

3 июня, 13:57 9207

XX2BEK ВИДЕО НОВОСТИ ПУБЛИКАЦИИ АНОНСЫ КАЛЕНДАРЬ РУБРИКИ Q Следите

БИОЛОГИЯ, БИОТЕХНОЛОГИИ | МЕДИЦИНА, ФИЗИОЛОГИЯ, ЗДОРОВЬЕ

**Российские онкологи предложили новый способ борьбы с тошнотой и рвотой при химиотерапии**

3 июня



Actualité Sciences & Environnement

**Chimiothérapie: un médicament pour faire disparaître la nausée**

Par Cyrille Vanlerberghé | Mis à jour le 05/06/2019 à 14:50 / Publié le 04/06/2019 à 18:00

# RESULTS OF THE SUPPORTED RESEARCH (2)

## A DIAGNOSTIC TEST FOR DETECTION OF TUMOR CELL RESISTANCE TO TARGETED THERAPY OF LUNG CANCER DEVELOPED

The aim of this project was to develop a diagnostic method to detect one of the tumor cells resistance mechanisms to targeted therapy, i.e., the third generation (the latest among the approved drugs) tyrosine kinase inhibitors (TKIs) in EGFR-mutated non-small cell lung cancer.



Within the scope of the project, a diagnostic platform for C797S mutation detection in circulating tumor DNA in blood plasma was successfully developed. This test is intended for the treatment efficacy monitoring, timely identification of disease progression in order to determine tactics of further therapy in case of tumor resistance to the drug being used.

The clinical part of the project included detection of resistance mutation C797S in circulating tumor DNA in a group of patients who received osimertinib (third generation TKI) as a second-line treatment of non-small-cell lung cancer.

The research results are being published in medical journals and presented at scientific meetings.

# COMPETITIONS AND GRANTS (1)

<p><b>COMPETITION IN ONCOIMMUNOLOGY</b> Code: 2018-02</p> <p><b>Specifics:</b></p> <ul style="list-style-type: none"> <li>• Pre-registration required</li> <li>• Application limited to 5 pages</li> </ul>	<p><b><u>RESEARCH PROJECTS COMPETITION FUNDED JOINTLY BY THE NPO “FOUNDATION FOR CANCER RESEARCH SUPPORT” (RAKFOND) AND SCISTORELAB, LLC</u></b></p> <ul style="list-style-type: none"> <li>• For researchers in Russian entities</li> <li>• Scientific research projects in oncoimmunology, immunotherapy, immunoprophylaxis, immunodiagnostics, and immune cell gene therapy</li> <li>• Working full-time or part-time (at least 50%) in organization / institution conducting research in oncology</li> </ul>
<p><b>Budget</b></p>	<p>1) reagents and consumables from SciStoreLab’s catalog with the total value of 150 000 rubles; 2) funding from RakFond up to 100 000 rubles.</p>
<p><b>Timeline</b></p>	<p>Applications open date: December 12, 2018 Applications due date: February 15, 2019 Formal compliance review finished: February 22, 2019 Scientific reviews in: March 22, 2019 <a href="#">Notice of award:</a> April 5, 2019</p>
<p><b>Winner</b></p>	<p><a href="#">Emil Bulatov</a> (Kazan Federal University)</p>

# WINNER OF THE ONCOIMMUNOLOGY COMPETITION

Jointly with [SciStoreLab](#)



**EMIL BULATOV, PH.D.**

**LEADING RESEARCHER, KAZAN FEDERAL UNIVERSITY**

**Project:** Investigating efficacy mechanisms of T cells with chimeric antigen receptor (CAR-T) against solid tumors

“In a broad sense, our goal is to “teach” human immune cells to fight tumor effectively. Therefore, we study CAR-T cells activity in lab tumor models. In prospect, our results will support the development of local biomedical cell products for the treatment of solid tumors. The research is conducted by us in collaboration with the V.A. Almazov National Medical Research Center (Saint-Petersburg) and has been recently supported by a 4-year grant from the Russian Science Foundation.”

[https://www.rakfond.org/en/bulatov-2018-02\\_en/](https://www.rakfond.org/en/bulatov-2018-02_en/)

# COMPETITIONS AND GRANTS (2)

<p><b>CLINICAL RESEARCH COMPETITION</b>  <b>Code:</b> 2019-01</p> <p><b>Specifics:</b></p> <ul style="list-style-type: none"> <li>• Pre-registration required</li> <li>• Application limited to 7 pages</li> </ul>	<p><u><a href="#">RAKFOND COMPETITION OF CLINICAL RESEARCH PROJECTS IN ONCOLOGY</a></u></p> <ul style="list-style-type: none"> <li>• Randomized clinical trials in oncology and related areas, including cancer prevention, diagnostics, monitoring and treatment, rehabilitation and quality of life of cancer patients</li> <li>• Oncology investigators based in Russia, working full-time or part-time (at least 50%) in organization / institution conducting research in oncology or related fields</li> </ul>
<p><b>Budget</b></p>	<ol style="list-style-type: none"> <li>1) Grant up to 500 000 rubles for the clinical study conduct</li> <li>2) Access to online service for clinical trials management <a href="#">Enrollme.ru</a></li> <li>3) Expert assistance in the clinical trial statistical design and data analysis</li> </ol>
<p><b>Timeline</b></p>	<p>Applications open date: April 25, 2019</p> <p>Application due date: July 1, 2019 (10 received)</p> <p>Formal compliance review finished: July 15, 2019 (6 sent for scientific review)</p> <p>Expert reviews: August 30, 2019 (at least 3 per application)</p> <p><u><a href="#">Notice of award:</a></u> September 20, 2019</p>
<p><b>Winners</b></p>	<ol style="list-style-type: none"> <li>1) <a href="#">Natalya Risinskaya</a> (National Medical Research Center of Hematology)</li> <li>2) <a href="#">Alexey Rumyantsev</a> (N.N. Blokhin National Medical Research Center of Oncology)</li> </ol>

# WINNERS OF THE CLINICAL RESEARCH COMPETITION

**NATALYA RISINSKAYA**



**Federal Budgetary State Institution “National Medical Research Center of Hematology”**

**Project:** Loss of heterozygosity in the short tandem repeat (STR) loci found in tumor DNA of ALL patients as a factor predicting poor outcome

**Funding amount :** 250 000 rubles

**Description:** [https://www.rakfond.org/en/risinskaya-2019-01\\_en/](https://www.rakfond.org/en/risinskaya-2019-01_en/)

**ALEXEY RUMYANTSEV**



**Federal Budgetary State Institution “N.N. Blokhin National Medical Research Center of Oncology”**

**Project:** Randomized multicenter phase II trial to assess the efficacy of platinum-based chemotherapy vs standard non-platinum therapy in patients with platinum-resistant recurrent ovarian cancer (EPITROC)

**Funding amount :** 463 000 rubles

**Description:** [https://www.rakfond.org/en/rumyantsev-2019-01\\_en/](https://www.rakfond.org/en/rumyantsev-2019-01_en/)

# AWARD FOR THE BEST RESEARCH

## RAKFOND AND RUSSCO AWARD FOR THE BEST RESEARCH

- Oncology investigators based in Russia
- Research results selected by the scientific committee to be presented at the **XXIII Russian Oncology Congress** during the session "Results of Russian Studies" on November 12, 2019.

Award: 50 000 rubles

VALERIYA SAYEVETS



CHELYABINSK REGIONAL CLINICAL CENTER FOR ONCOLOGY AND  
NUCLEAR MEDICINE

**Project:** The final analysis of the non-interventional study OVATAR: diagnostic and therapeutic approaches to the treatment of ovarian cancer in Russia. Group analysis with BRCA mutations

[Project description](#)

# EVENTS AND MATERIALS

## XXIII RUSSIAN ONCOLOGY CONGRESS

**12** НОЯБРЯ  
с 9:30 до 11:00

Крокус Экспо



XXIII Российский онкологический конгресс

**МАСТЕР-КЛАСС RUSSCO-РАКФОНД:**


**Клинические исследования в онкологии. Что необходимо для инициации собственного клинического исследования?**

Joint RUSSCO/RakFond workshop on conducting clinical trials in oncology



RakFond and RUSSCO Award for the Best Research

Brochure for researchers on the regulatory support of clinical trials (jointly with [ACTO](#) and [RUSSCO](#))



[View pdf](#)

SERIES OF INTERVIEWS WITH EXPERTS

[Watch interviews](#)

ARTICLES & REVIEWS about recent scientific advances in oncology

[Read and watch](#)

# **3. FUNDRAISING & FINANCIALS**



# FINANCIAL REPORT 2019

In 2019, we raised 1 661 670,03 rubles\*

Total expenditures were 1 458 124,91 rubles

234 000.00 ₺ **FUNDING BY SOURCE**

**TYPES OF EXPENDITURES**



\*including 45 748 rubles – return of unexpended grant funds RFP-2018-01-YS-ECI

Administrative expenditures include rent, accounting and legal council, annual audit, salary, banking.

# EXPENDITURES

## 1. Research Funding – 863 000 rubles

- ✓ [Grant 2018-02 – 100 000 rubles](#)
- ✓ [Grant 2019-01 – 250 000 rubles](#)
- ✓ [Grant 2019-01 – 463 000 rubles](#)
- ✓ [Award 2019-01-AWARD – 50 000 rubles](#)

## 2. Fundraising – 10 000 rubles

- ✓ [Meet For Charity](#) services of fundraising

## 2. Administrative – 585 124.91 rubles

- ✓ Rent
- ✓ Accounting and legal council
- ✓ Annual audit
- ✓ Salary
- ✓ Banking

## **4. PARTNERSHIPS & COLLABORATIONS**



ПРОВЕРЕНО ФОНДОМ  
«НУЖНА ПОМОЩЬ»

# OUR SUPPORTERS



Strategic Cooperation  
[rosoncweb.ru](http://rosoncweb.ru)

 **НУЖНА ПОМОЩЬ**

Fundraising  
[nuzhnapomosh.ru/](http://nuzhnapomosh.ru/)

**P R O  
C H A  
R I T Y**

Professional volunteers  
[procharity.ru](http://procharity.ru)



Online platform for clinical trials  
management  
[enrollme.ru](http://enrollme.ru)



Joint Competition  
[sci-store.ru](http://sci-store.ru)



[unim.su](http://unim.su)



[oct-clinicaltrials.com](http://oct-clinicaltrials.com)



[exactelabs.com](http://exactelabs.com)



Information Support  
[u-art.ru](http://u-art.ru)



MEET FOR CHARITY  
Fundraising  
[meetforcharity.today](http://meetforcharity.today)



[goshprojects.org](http://goshprojects.org)



[nomia.net](http://nomia.net)

## CONTACTS

**E-mail:** [info@rakfond.org](mailto:info@rakfond.org)

**Foundation's Director:**

Yuliya Atamanyuk | [director@rakfond.org](mailto:director@rakfond.org)

**Founder and Chair of the Board of Directors:**

Kristina Zakurdaeva | [christina@rakfond.org](mailto:christina@rakfond.org)

**Funding & Partnerships:**

| [finance@rakfond.org](mailto:finance@rakfond.org)

**Funding programs**

| [grant@rakfond.org](mailto:grant@rakfond.org)

**Volunteering:**

Maria Shevchenko | [volunteer@rakfond.org](mailto:volunteer@rakfond.org)

**Mass media and public relationships:**

| [media@rakfond.org](mailto:media@rakfond.org)



**CANCER**  
**foundation**

[rakfond.org/en](http://rakfond.org/en)

Advancing the Day when  
Cancer is Defeated



[rak\\_fond](https://www.instagram.com/rak_fond)



**RakFond**



[www.rakfond.org](http://www.rakfond.org)